<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Usual doses of single agent long-acting muscarinic antagonists (anticholinergic) for COPD</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Usual doses of single agent long-acting muscarinic antagonists (anticholinergic) for COPD</h1>
<div class="graphic"><div class="figure"><div class="ttl">Usual doses of single agent long-acting muscarinic antagonists (anticholinergic) for COPD</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup> <colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Agent</td> <td class="subtitle1_left">Brand name</td> <td class="subtitle1_left">Dosing</td> </tr> <tr> <td rowspan="2">Aclidinium</td> <td>Tudorza Pressair (United States)</td> <td rowspan="2">DPI:<sup>*</sup> 1 inhalation (400 mcg/actuation) twice daily</td> </tr> <tr> <td>Tudorza Genuair (Canada)</td> </tr> <tr class="highlight_lght_gray_text"> <td>Glycopyrrolate (known as glycopyrronium in Canada and Europe)<sup>¶</sup></td> <td>Seebri Breezhaler (Canada, UK, EU, other areas)</td> <td>DPI:<sup>*</sup> Inhale contents of 1 capsule (50 mcg/capsule<sup>Δ</sup>) once daily</td> </tr> <tr> <td rowspan="2">Tiotropium<sup>¶</sup></td> <td>Spiriva HandiHaler (United States), Spiriva (Canada)</td> <td>DPI:<sup>*</sup> Inhale contents of 1 capsule (18 mcg/capsule) once daily</td> </tr> <tr> <td>Spiriva Respimat (United States, Canada)</td> <td>SMI:<sup>◊</sup> 2 inhalations (2.5 mcg/actuation) once daily</td> </tr> <tr class="highlight_lght_gray_text"> <td>Umeclidinium</td> <td>Incruse Ellipta (United States, Canada)</td> <td>DPI:<sup>*</sup> 1 inhalation (62.5 mcg/actuation) once daily</td> </tr> <tr> <td>Revefenacin<sup>§</sup></td> <td>Yupelri (United States)</td> <td>Solution for nebulization: Inhale contents of 1 vial (175 mcg/3 mL) once daily via standard jet nebulizer<sup>¥</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; SMI: soft mist inhaler.</p>
<p>* DPIs contain lactose and may contain milk protein, which may put patients with milk protein allergy at risk.</p>
<p>¶ Use in patients with moderate to severe renal dysfunction should be based on consideration of expected benefits compared with potential risk of reduced clearance; patients should be monitored for anticholinergic adverse effects.</p>
<p>Δ Glycopyrrolate (United States name) is called glycopyrronium in other countries. The dose of glycopyrrolate (glycopyrronium) is expressed variably, depending upon the country. In the United States, the glycopyrrolate (glycopyrronium) dose is expressed as the amount of bromide salt delivered from the mouthpiece. In Canada, the dose is expressed as the amount of glycopyrronium base per capsule.</p>
<p>◊ Tiotropium SMI is available as multiple strengths (ie, 1.25 mcg/actuation and 2.5 mcg/actuation). For COPD, the 2.5 mcg/actuation preparation should be used.</p>
<p>§ Revefenacin use is not recommended in patients with hepatic impairment.</p>
¥ Do not dilute or mix with other medications.</div><div class="graphic_reference">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 122118 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
